New pill could tame stubborn hives
NCT ID NCT06865651
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called remibrutinib (a tablet) against a placebo in 44 adults with chronic hives (either spontaneous or triggered by things like pressure or cold). The goal is to see if it reduces symptoms like itching and burning, and how it works in the body. Participants take the drug or placebo for 12 weeks, and researchers track symptom control and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
remibrutinib (a tablet drug)
What this could lead to
If it works, this could point toward a new treatment option for people with chronic hives that are not well controlled by current antihistamines.
What could go wrong
This is an early phase 2 study with only 44 participants, so results may not apply to everyone. The drug may not prove more effective than placebo, and side effects are still being explored.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Endeavor Health
RECRUITINGGlenview, Illinois, 60077, United States
Contact Email: •••••@•••••
Contact
-
Novartis Investigative Site
RECRUITINGGrenoble, 38043, France
-
Novartis Investigative Site
RECRUITINGMontpellier, 34295, France
-
Novartis Investigative Site
RECRUITINGParis, 75970, France
-
Novartis Investigative Site
RECRUITINGPierre-Bénite, 69495, France
-
Novartis Investigative Site
RECRUITINGDresden, Saxony, 01307, Germany
-
Novartis Investigative Site
RECRUITINGBerlin, 13353, Germany
-
Novartis Investigative Site
WITHDRAWNMainz, 55131, Germany
-
Novartis Investigative Site
RECRUITINGTübingen, 72076, Germany
-
Novartis Investigative Site
RECRUITINGPoznan, 61-731, Poland
-
Novartis Investigative Site
RECRUITINGRzeszów, 35 055, Poland
-
Novartis Investigative Site
RECRUITINGWarsaw, 02-962, Poland
-
Novartis Investigative Site
RECRUITINGBarcelona, Catalonia, 08003, Spain
-
Novartis Investigative Site
RECRUITINGPamplona, Navarre, 31008, Spain
-
Novartis Investigative Site
RECRUITINGAlicante, 03010, Spain
-
Novartis Investigative Site
RECRUITINGMadrid, 28006, Spain
-
Ziaderm Research LLC
RECRUITINGNorth Miami Beach, Florida, 33162, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact